Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcimimetics and hyperparathyroidism.

Linda J Krebs1

  • 1Center for Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3101, USA. krebs@up.uchc.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|November 13, 2004
PubMed
Summary

The calcium-sensing receptor (CaSR) regulates parathyroid hormone secretion. Calcimimetics targeting CaSR show promise for treating hyperparathyroidism (HPT).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HRPT2 mutational analysis of typical sporadic parathyroid adenomas.

The Journal of clinical endocrinology and metabolism·2005
Same author

Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro.

International journal of oncology·2002
Same author

Molecular pathogenesis of primary hyperparathyroidism.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2002
Same author

A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers.

Oral oncology·2002

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • The calcium-sensing receptor (CaSR) critically controls parathyroid hormone (PTH) secretion and parathyroid cell growth.
  • Dysregulation of CaSR signaling is implicated in various forms of hyperparathyroidism (HPT).

Purpose of the Study:

  • To review the CaSR's role in HPT pathogenesis.
  • To explore the therapeutic potential of targeting CaSR for HPT treatment.

Main Methods:

  • Literature review of CaSR function in HPT.
  • Analysis of clinical trial data for calcimimetic efficacy in HPT.

Main Results:

  • Calcimimetics, as CaSR agonists/activators, modulate parathyroid cell function by enhancing responses to extracellular calcium.
  • Clinical trials indicate calcimimetics are effective in treating primary and secondary HPT, including HPT from parathyroid carcinoma.

Conclusions:

  • The CaSR represents a viable therapeutic target for managing HPT.
  • Calcimimetic agents offer a promising therapeutic strategy for diverse HPT conditions.

Related Experiment Videos